SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) from ProteoGenix; catalogue KPTX387; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) is a cutting-edge diagnostic tool used for the detection and quantification of neutralizing antibodies against the B.1.351 variant of the SARS-CoV-2 virus. This variant, also known as the South African variant, contains three key mutations in the spike protein: K417N, E484K, and N501Y. These mutations have been found to increase the virus’s transmissibility and potentially decrease the effectiveness of some current vaccines.
The SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) is a lateral flow immunoassay that utilizes recombinant SARS-CoV-2 spike protein and ACE2 receptor protein to detect neutralizing antibodies in patient samples. The kit contains all necessary components, including sample diluent, buffer, and control samples, for easy and efficient testing. The test is performed on a small sample of blood or plasma and provides results within 20 minutes.
The SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) works by mimicking the interaction between the spike protein of the B.1.351 variant and the ACE2 receptor protein. Neutralizing antibodies present in the patient sample will bind to the spike protein, preventing it from binding to the ACE2 receptor. This results in a visible line on the test strip, indicating the presence of neutralizing antibodies against the B.1.351 variant. The intensity of the line is proportional to the amount of neutralizing antibodies present in the sample, allowing for quantification of antibody levels.
The SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) has multiple applications in the fight against COVID-19. Firstly, it can be used as a diagnostic tool to identify individuals who have been infected with the B.1.351 variant. This information is crucial for tracking the spread of the variant and implementing targeted control measures. Additionally, the test can be used to monitor the immune response of individuals who have been vaccinated against COVID-19. As the B.1.351 variant has shown some resistance to current vaccines, this test can help determine the effectiveness of vaccination against this specific variant.
The B.1.351 variant, with its key mutations in the spike protein, has become a major therapeutic target in the fight against COVID-19. The SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) plays a crucial role in identifying and monitoring the spread of this variant. It can also aid in the development of new therapeutics and vaccines targeting the B.1.351 variant by providing a reliable and efficient method for measuring neutralizing antibody levels.
Aside from its diagnostic and therapeutic applications, the SARS-CoV-2 Surrogate Virus Neutralization Test Kit (B.1.351/K417N,E484K,N501Y) also has significant research use. It can be used to study the immune response to the B.1.351 variant and to evaluate the effectiveness of potential treatments and vaccines. The test kit provides a quick and easy way to measure neutralizing antibody levels, making it a valuable tool for researchers studying the B.1.351 variant and its impact on the COVID-19 pandemic.
ProteoGenix catalogue number KPTX387. For research use only.
Applications: ELISA.
Available configurations: 96T.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
